Analysts Anticipate Advanced Micro Devices To Record $3.62 Billion In Q2 Revenues

Advanced Micro Devices (NASDAQ: AMD) will be reporting their second quarter financial results on July 27 after markets close. Analysts have a consensus $106.88 12-month price target on the company, via a total of 42 analysts, with seven analysts having strong buy ratings. 19 analysts meanwhile have buy ratings, 15 have hold ratings, and one analyst has a sell rating on the company. The street high comes from Elazar Advisors with a $161.70 price target, and the lowest target sits at $74 from KGI Greater China.

29 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 29 analysts is $3.62 billion; this number has been revised upwards from $2.83 billion at the start of the year. The highest revenue estimate is $3.82 billion, while the lowest is $3.5 billion.

Onto EBITDA estimates, there are currently only 7 analysts who have second-quarter EBITDA estimates. The mean is currently $884.4 million, with this number having been revised upwards from $598.54 million at the start of the year. The street high estimate currently sits at $900 million in EBITDA and the lowest is $850 million.

Analysts estimate that quarterly earnings per share will come in at $0.47, with this number being slightly revised upwards from $0.33 at the start of the year. Street high is $0.51 and the lowest estimate is $0.40 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Agnico Q1 Earnings Results Overshadowed By A Sinking Gold Price

Why More People Are Starting to Feel Broke | Darrell Thomas – VRIC Media

Newmont Q1 Earnings: A Billion In Free Cash Flow… A Month!

Recommended

Selkirk Copper Strikes New Lens Beneath Old Pit, Launches 50,000 Metre Phase 2 Program

Silver47 Pulls High-Grade Gold and Silver Assays from Nevada Vein Network At Kennedy

Related News

Medipharm Labs Sees Canaccord Drop Price Target To $0.75

On May 17th, MediPharm Labs (TSX: LABS) Labs reported their first-quarter financials. The company announced...

Tuesday, May 18, 2021, 05:32:00 PM

Lundin Mining: BMO Lowers Targets, Rating Based On Expected Lackluster News Flow

On August 19, BMO Capital Markets lowered their 12-month price target on Lundin Mining Corporation...

Friday, August 20, 2021, 11:21:00 AM

Couche-Tard: Canaccord Reiterates $51 Price Target After Q3 Results

On November 23rd, Alimentation Couche-Tard Inc. (TSX: ATD.B) announced its fiscal second quarter results. The...

Friday, November 26, 2021, 04:32:00 PM

Microsoft: BMO Cuts Target To $270 After Weak Q1 Earnings

Microsoft (Nasdaq: MSFT) last week released their first quarter results for fiscal 2023, which ended...

Sunday, October 30, 2022, 01:31:00 PM

Curaleaf: Canaccord Reiterates $22 Price Target Following Secured Note Issuance

On December 16th, Curaleaf Holdings (CSE: CURA) announced the closing of US$425 million 8% senior...

Thursday, December 30, 2021, 04:38:00 PM